Patents Issued in June 27, 2019
  • Publication number: 20190194263
    Abstract: The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases.
    Type: Application
    Filed: September 18, 2018
    Publication date: June 27, 2019
    Applicant: Oral Health Australia PTY Ltd
    Inventors: Eric Charles REYNOLDS, Neil Martin O'BRIEN SIMPSON, Keith J. CROSS, Nada SLAKESKI
  • Publication number: 20190194264
    Abstract: Described herein are polypeptides comprising a lipoprotein export signal, polypeptide precursors comprising a lipoprotein export signal, nucleic acids encoding said polypeptides or polypeptide precursors, recombinant expression vectors comprising nucleic acids encoding said lipoprotein export signal and/or polypeptides or polypeptide precursors, and 5 recombinant host cells comprising these vectors. The application further provides uses of these polypeptides, polypeptide precursors, nucleic acids, recombinant expression vectors and recombinant host cells.
    Type: Application
    Filed: August 11, 2017
    Publication date: June 27, 2019
    Applicant: UNIVERSITÉ DE NAMUR
    Inventors: Frédéric André Lauber, Francesco Renzi, Guy Richard Comelis
  • Publication number: 20190194265
    Abstract: Protein replacement therapy for patients with hemophilia or other inherited protein deficiencies is often complicated by pathogenic antibody responses, including antibodies that neutralize the therapeutic protein or that predispose to potentially life-threatening anaphylactic reactions by formation of IgE. Using murine and canine hemophilia as a model, we have developed a prophylactic protocol against such responses that is non-invasive and does not include immune suppression or genetic manipulation of the patient's cells. Oral delivery of a coagulation factor expressed in chloroplasts, bioencapsulated in plant cells, effectively blocked formation of inhibitory antibodies in protein replacement therapy. Inhibitor titers were mostly undetectable and up to 100-fold lower in treated subjects when compared to controls. Moreover, this treatment eliminated fatal anaphylactic reactions that occurred after four to six exposures to intravenous coagulation factor protein.
    Type: Application
    Filed: March 12, 2019
    Publication date: June 27, 2019
    Inventors: Roland W. Herzog, Henry Daniell
  • Publication number: 20190194266
    Abstract: Compositions having pesticidal activity and methods for their use are provided. Compositions include isolated and recombinant polypeptide sequences having pesticidal activity, recombinant and synthetic nucleic acid molecules encoding the pesticidal polypeptides, DNA constructs comprising the nucleic acid molecules, vectors comprising the nucleic acid molecules, host cells comprising the vectors, and antibodies to the pesticidal polypeptides. Nucleotide sequences encoding the polypeptides provided herein can be used in DNA constructs or expression cassettes for transformation and expression in organisms of interest. The compositions and methods provided herein are useful for the production of organisms with enhanced pest resistance or tolerance. Transgenic plants and seeds comprising a nucleotide sequence that encodes a pesticidal protein of the invention are also provided. Methods are provided for producing the polypeptides disclosed herein, and for using those polypeptides for controlling a pest.
    Type: Application
    Filed: December 20, 2018
    Publication date: June 27, 2019
    Applicant: AgBiome, Inc.
    Inventors: Kira Bulazel Roberts, Rebecca E. Thayer, Jessica Parks
  • Publication number: 20190194267
    Abstract: The present disclosure provides genetically modified microorganisms (e.g., bacteria or yeast) with enhanced mucin-binding and/or cell-adhesion properties. For example, the present disclosure provides bacteria exhibiting increased in vitro binding to Caco-2 cells, and increased in vitro binding to mucins. Such microorganisms (e.g., bacteria) can be used, e.g., to deliver bioactive polypeptides to the gastrointestinal tract of a mammalian subject. Modifying the microorganism in the described manner allows for the modulation of gastrointestinal retention and transit times for the microorganism (e.g., bacterium). Exemplary microorganisms (e.g., lactic acid bacteria, such as Lactococcus lactis) contain an exogenous nucleic acid encoding a fusion protein containing a cell-adherence polypeptide, such as CmbA, and a mucin-binding polypeptide, such as a trefoil factor (TFF), e.g., human TFF3. The current disclosure further provides method for making and using the described microorganisms (e.g., bacteria).
    Type: Application
    Filed: September 11, 2017
    Publication date: June 27, 2019
    Applicant: INTREXON ACTOBIOTICS N.V.
    Inventors: Lothar STEIDLER, Klaas VANDENBROUCKE
  • Publication number: 20190194268
    Abstract: Multimeric defensin proteins (MD) containing at least two defensin peptides joined by a spacer peptide that is resistant to endoproteinase cleavage are disclosed along with compositions comprising the MD proteins and transgenic or genetically edited plants or microorganisms that express the MD to inhibit growth of pathogenic fungi. Such MD proteins, compositions, plants, and microorganisms can provide for improved inhibition of fungal growth when compared to a protein containing only one of the defensin peptides found in the MD.
    Type: Application
    Filed: March 10, 2017
    Publication date: June 27, 2019
    Inventors: Dilip M Shah, Siva linga sasanka Velivelli, Kazi Tariqul Islam
  • Publication number: 20190194269
    Abstract: Polynucleotides and polypeptides useful in the manufacture of a class of chemical compounds known as alkaloids are provided. The polynucleotides and polypeptides may be used to synthesize alkaloids, including reticuline, thebaine and morphine, in vivo and in vitro. The polynucleotides further may be used to examine the presence of the polynucleotides in a cell or a cell extract, and to modulate expression thereof in living cells.
    Type: Application
    Filed: June 27, 2017
    Publication date: June 27, 2019
    Applicants: INTREXON CORPORATION, SERTURNER CORP.
    Inventors: Peter James FACCHINI, Joseph E. TUCKER
  • Publication number: 20190194270
    Abstract: The present disclosure provides a method of producing enzyme-specific inhibitors or substrate binding partners comprising: identifying active site residues of the substrate in the enzyme substrate complex or in substrate binding partner-substrate complex; randomizing the active site residues to produce a combinatorial library of substrate variants; and selecting substrate variants that inhibit enzyme activity or bind substrate as substrate-specific binding partners. The present disclosure also provides ubiquitin enzyme specific inhibitors and ubiquitin variants that bind ubiquitin interaction motifs.
    Type: Application
    Filed: January 4, 2019
    Publication date: June 27, 2019
    Inventors: Sachdev Sidhu, Linda Beatty, Andreas Ernst
  • Publication number: 20190194271
    Abstract: The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway, the compositions of these fusion proteins, as well as methods for producing and using the same.
    Type: Application
    Filed: February 22, 2019
    Publication date: June 27, 2019
    Inventors: Pei-Tzu WU, Jia-Hau SHIU, Madhu CHERUKURY, Tan NGUYEN, Kevin Zen
  • Publication number: 20190194272
    Abstract: The present disclosure provides recombinant polypeptides, nucleic acids encoding the recombinant polypeptides and methods for using these polypeptides and/or nucleic acids in enhancing or inducing an immune response in a subject in need thereof. The present disclosure also provides methods of treating a cell proliferative disorder, such as cancer, by administering the disclosed polypeptides and/or nucleic acids to a subject in need thereof.
    Type: Application
    Filed: September 21, 2018
    Publication date: June 27, 2019
    Inventors: Ya-Huei Chen, Ting-Long Lin
  • Publication number: 20190194273
    Abstract: The present disclosure provides recombinant polypeptides, nucleic acids encoding the recombinant polypeptides and methods for using these polypeptides and/or nucleic acids in enhancing or inducing an immune response in a subject in need thereof. The present disclosure also provides methods of treating a cell proliferative disorder, such as cancer, by administering the disclosed polypeptides and/or nucleic acids to a subject in need thereof.
    Type: Application
    Filed: September 21, 2018
    Publication date: June 27, 2019
    Inventors: Ya-Huei Chen, Ting-Long Lin
  • Publication number: 20190194274
    Abstract: The present disclosure provides recombinant polypeptides, nucleic acids encoding the recombinant polypeptides and methods for using these polypeptides and/or nucleic acids in enhancing or inducing an immune response in a subject in need thereof. The present disclosure also provides methods of treating a cell proliferative disorder, such as cancer, by administering the disclosed polypeptides and/or nucleic acids to a subject in need thereof.
    Type: Application
    Filed: September 21, 2018
    Publication date: June 27, 2019
    Inventors: Ya-Huei Chen, Ting-Long Lin
  • Publication number: 20190194275
    Abstract: Described herein is a novel, mitochondrial encoded, open reading frame, that leads to the production of a new mitochondrial peptide. Residing within the ND-Two subunit, a specific small nucleotide polymorphism disrupts expression of this mitochondrial peptide, and is correlated with an increase in obesity and diabetes, particularly in certain ethnic populations. In vitro administration of the peptide increases insulin secretion, decreases fat accumulation and improves glucose uptake in muscle cell. Antibodies generated against the peptide can be used for detecting peptide deficiency, in addition to SNP detection, supporting diagnostic approaches. In vivo studies further revealed that administration of the peptide improves glucose tolerance, thereby providing a new therapeutic avenue for a novel diabetes therapy and decreases bodyweight, thus serving as a novel obesity therapy. Generation of synthetic analogs further enhance or abrogated activity relative to the natural peptide.
    Type: Application
    Filed: June 23, 2017
    Publication date: June 27, 2019
    Applicant: University of Southern California
    Inventors: Pinchas Cohen, Kelvin Yen
  • Publication number: 20190194276
    Abstract: This document provides methods and materials for treating cancer (e.g., chemotherapeutic resistant cancer). For example, compositions containing a phosphorylation-mimicking peptide (e.g., a phosphorylation-mimicking FOXO1-derived peptide) to treat a mammal having cancer (e.g., to reduce the number of cancer cells in a mammal) and methods of using such compositions are provided. This document also provides methods of treating a mammal having cancer (e.g., to reduce the number of cancer cells in a mammal) by administering a phosphorylation-mimicking FOXO1-derived peptide to the mammal.
    Type: Application
    Filed: March 8, 2017
    Publication date: June 27, 2019
    Applicant: Mayo Foundation for Medical Education and Research
    Inventor: Haojie Huang
  • Publication number: 20190194277
    Abstract: Provided are novel methods of treating generalized myasthenia gravis in a subject. These methods generally comprise administering to the subject an effective amount of an isolated FcRn antagonist. In certain embodiments the FcRn antagonist binds to FcRn with increased affinity and reduced pH dependence relative to native Fc region.
    Type: Application
    Filed: December 7, 2018
    Publication date: June 27, 2019
    Inventors: Johannes de Haard, Torsten Dreier, Peter Ulrichts, Antonio Guglietta, Nicolas Leupin
  • Publication number: 20190194278
    Abstract: The invention provides for novel immunostimulating peptides, peptide constructs and compositions. Further, the invention provides for methods of treatment utilising the peptides, peptide constructs and compositions.
    Type: Application
    Filed: August 23, 2017
    Publication date: June 27, 2019
    Applicant: AIMVION A/S
    Inventor: Shervin Bahrami
  • Publication number: 20190194279
    Abstract: Peptides derived from the N-terminal region of granulin have activity in promoting cell proliferation, migration and/or wound healing. Furthermore, an additional disulphide bond may be engineered into such peptides to improve or otherwise modify the folding of the peptide. The peptides may also be modified such as at proline residues improve the ability of the peptide to promote cell proliferation.
    Type: Application
    Filed: September 4, 2017
    Publication date: June 27, 2019
    Inventors: Alex Loukas, Michael Smout, Norelle Daly
  • Publication number: 20190194280
    Abstract: The present disclosure is directed to individual A? peptide immunogen constructs, peptide compositions comprising these A? peptide immunogen constructs and mixtures thereof, pharmaceutical compositions including vaccine formulations comprising these A? peptide immunogen constructs, with the individual A? peptide immunogen constructs having the N-terminus of the A? peptide as the B cell (B) epitopes linked through spacer residue(s) to heterologous T helper cell (Th) epitopes derived from pathogen proteins that act together to stimulate the generation of highly specific antibodies directed against the N-terminus of the A? peptide offering protective immune responses to patients at risk for, or with, Alzheimer's Disease.
    Type: Application
    Filed: December 31, 2018
    Publication date: June 27, 2019
    Inventor: Chang Yi Wang
  • Publication number: 20190194281
    Abstract: The invention creates engineered surface protein expression on vesicles for specific targeting and delivery of agents to autophagic and apoptotic cells. Moreover, the vesicles of the invention can achieve a synergistic effect on the targeting and drug delivery to autophagic and apoptotic cells and autophagic and apoptotic cells-containing tissues.
    Type: Application
    Filed: December 27, 2017
    Publication date: June 27, 2019
    Inventors: Hsin-Hou CHANG, Der-Shan SUN
  • Publication number: 20190194282
    Abstract: Described herein are recombinant chimeric proteins comprising a double stranded RNA (dsRNA) binding domain and a cancer-cell targeting domain for targeting of dsRNA to cancer cells. Methods of use of the described chimeric proteins are also provided herein.
    Type: Application
    Filed: December 15, 2016
    Publication date: June 27, 2019
    Inventors: Alexander LEVITZKI, Yael LANGUT
  • Publication number: 20190194283
    Abstract: Provided herein are immunomodulatory polypeptides containing first and second submits of a cytokine or a chemokine connected by a joining region containing a targeting moiety that binds to a target molecule. In some aspects, the disclosure further relates to engineered cells and compositions comprising the immunomodulatory polypeptides and methods for their administration to subjects. In some embodiments, the cells engineered to contain the immunomodulatory polypeptide, such as T cells, further contain a genetically engineered antigen receptor that specifically binds to antigens, such as a chimeric antigen receptor (CAR). In some embodiments, features of the polypeptides, engineered cells, and methods provide for improved treatment of diseases or disorders, such as by reducing adverse effects of cytokine or chemokine therapy, or increasing activity, efficacy and/or persistence or decreasing immunogenicity of adoptive cell therapy.
    Type: Application
    Filed: July 28, 2017
    Publication date: June 27, 2019
    Applicant: Juno Therapeutics, Inc.
    Inventors: Collin HAUSKINS, Allen EBENS
  • Publication number: 20190194284
    Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.
    Type: Application
    Filed: May 12, 2017
    Publication date: June 27, 2019
    Inventors: Nikolai KLEY, Jan TAVERNIER, Frank PEELMAN
  • Publication number: 20190194285
    Abstract: The present invention relates to novel insulin analogues and derivatives thereof, such as acylated insulin analogues, and their pharmaceutical use, in particular in the treatment or prevention of medical conditions relating to diabetes, obesity and cardiovascular diseases.
    Type: Application
    Filed: August 16, 2018
    Publication date: June 27, 2019
    Inventors: Grith Skytte Olsen, Bo Falck Hansen, Lauge Schaeffer, Ingrid Pettersson, Rita Slaaby, Jakob Brandt
  • Publication number: 20190194286
    Abstract: In order to provide a membrane protein production method which does not require the step of solubilizing a membrane protein and which allows the membrane protein having an excellent quality to be obtained with a high yield, a method in accordance with an embodiment of the present invention includes: a step (a) of preparing a reaction solution for cell-free protein synthesis, the reaction solution containing (i) a template nucleic acid which encodes the membrane protein, (ii) a lipid, and (iii) a detergent which is contained at a concentration equal to or higher than a critical micelle concentration; and a step (b) of synthesizing the membrane protein while the concentration of the detergent in the reaction solution is maintained at a concentration equal to or higher than a critical micelle concentration.
    Type: Application
    Filed: July 29, 2016
    Publication date: June 27, 2019
    Inventor: Shigeyuki YOKOYAMA
  • Publication number: 20190194287
    Abstract: Methods and compositions for treating diseases or disorders of the nervous system using promoter-driven Designer Receptor Exclusively Activated by Designer Drugs (DREADDs) and DREADD agonists are disclosed.
    Type: Application
    Filed: August 31, 2017
    Publication date: June 27, 2019
    Inventors: Hannah E. BOWREY, Gary ASTON-JONES
  • Publication number: 20190194288
    Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
    Type: Application
    Filed: March 7, 2019
    Publication date: June 27, 2019
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Thomas BRENNAN, David BELLOVIN, David BUSHA, Barbara SENNINO
  • Publication number: 20190194289
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: March 11, 2019
    Publication date: June 27, 2019
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Publication number: 20190194290
    Abstract: Methods and materials for preventing and modulating atherosclerosis. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and atherosclerosis. The use of such peptides in reducing atherosclerosis, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. The use of such short peptides to lower LDL cholesterol. Methods and materials for detecting T-cells that express CD40 (Th40 cells).
    Type: Application
    Filed: November 8, 2018
    Publication date: June 27, 2019
    Applicant: OP-T LLC
    Inventors: David Hal Wagner, JR., Martin Glenn Yussman, Charles W. Henry
  • Publication number: 20190194291
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) one Fab domain capable of specific binding to a target cell antigen, (b) a Fc domain composed of a first and a second subunit capable of stable association, and (c) a first polypeptide comprising two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and a second polypeptide comprising one ectodomain of said TNF ligand family member or a fragment thereof, wherein the first polypeptide is fused at its N-terminus to the C-terminus of one of the subunits of the Fc domain and wherein the second polypeptide is fused at its N-terminus to the C-terminus of the other subunit of the Fc domain, wherein the TNF family ligand trimer-containing antigen binding molecule is monovalent for the binding to the target cell antigen.
    Type: Application
    Filed: November 8, 2018
    Publication date: June 27, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Ekkehard Moessner, Pablo Umana, Maria Amann, Christina Claus, Wei Xu
  • Publication number: 20190194292
    Abstract: A recombinant fusion protein is disclosed. The fusion protein comprises: (a) a CD55 peptide sequence, (b) a linker sequence C-terminal to the CD55 sequence, (c) a transmembrane domain C-terminal to the linker sequence, and (d) an intracellular domain C-terminal to the transmembrane domain. The fusion protein does not contain a GPI anchor. The fusion protein can be expressed with an N-terminal secretory signal peptide, which is cleaved to yield the mature protein on the surface of a cell line or an enveloped virus. An oncolytic virus expressing the fusion protein is resistant to complement inactivation and can be used to treat cancer.
    Type: Application
    Filed: May 10, 2018
    Publication date: June 27, 2019
    Inventors: Tianci LUO, Rene MOLINA, Gabriel CASTILLE
  • Publication number: 20190194293
    Abstract: The present disclosure provides soluble interferon receptors. The methods of the disclosure can be used to treat or prevent a condition associated with an abnormal immune response.
    Type: Application
    Filed: August 22, 2018
    Publication date: June 27, 2019
    Inventors: James Arthur POSADA, Pamela SMOLAK
  • Publication number: 20190194294
    Abstract: The purpose of the present invention is to provide an agent for restoring a visual function or an agent for preventing the deterioration in a visual function, which has an excellent visual function restoring ability. The agent for regenerating a visual function or the agent for preventing the deterioration in a visual function according to the present invention contains, as an active ingredient, a chimeric protein having both an amino acid sequence for a microorganism-origin ion-transporting receptor rhodopsin and an amino acid sequence for an animal-origin G-protein-coupled receptor rhodopsin. The chimeric protein is preferably one in which an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the amino acid sequence for the microorganism-origin ion-transporting receptor rhodopsin is substituted by an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the G-protein-coupled receptor rhodopsin.
    Type: Application
    Filed: September 1, 2017
    Publication date: June 27, 2019
    Inventors: Toshihide Kurihara, Yusaku Katada, Hiromitsu Kunimi, Kazuo Tsubota, Hideki Kandori
  • Publication number: 20190194295
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
    Type: Application
    Filed: December 5, 2018
    Publication date: June 27, 2019
    Inventors: Falko-Günter Falkner, Franziska Horling, Johannes Lengler, Hanspeter Rottensteiner, Friedrich Scheiflinger
  • Publication number: 20190194296
    Abstract: Provided herein are peptides that exhibit ApoE biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications.
    Type: Application
    Filed: March 12, 2019
    Publication date: June 27, 2019
    Inventors: Daniel T. Laskowitz, Hana Dawson, Brad Kolls
  • Publication number: 20190194297
    Abstract: This invention relates to the field of keratin extraction and recovery from keratinous animal body parts (KABP) including, but not limited to, hair, wool, nails, skins, feathers, hooves, claws and other body parts. More specifically, the invention relates to processes to extract keratin from KABP and hydrolyze it to keratin hydrolysates (KHs) using a thermal hydrolysis process (THP) and recover KHs by membrane filtration, in particular, using shear wave-induced ultra- or nano-membrane filtration (SWIUF) or a combination of SWIUF and reverse osmosis (RO), to select given molecular weight (MW) fractions of the protein or KHs or/and to increase the concentration of protein or KHs.
    Type: Application
    Filed: December 21, 2018
    Publication date: June 27, 2019
    Applicant: TOMORROW WATER
    Inventors: KEN TASAKI, LANCE KANEOKA
  • Publication number: 20190194298
    Abstract: Systems and methods for characterizing low molecular weight (LMW) protein drug product impurities are provided. One embodiment uses hydrophilic interaction chromatography (HILIC) coupled to mass spectrometry analysis. After removal of the N-linked glycans from the protein drug product, for example an antibody drug product, the elution of LMW impurities from the HILIC column was determined by the size of the molecular weight species. In some embodiments, the HILIC separation is performed under denaturing conditions, making the detection of LMW forms using this method highly comparable to both SDS-PAGE and CE-SDS methods. LMW drug product impurities include, but are not limited to light chain, half antibody, H2L, H2, HL, HC, peptide backbone-truncated species, and combinations thereof.
    Type: Application
    Filed: December 18, 2018
    Publication date: June 27, 2019
    Inventor: Shunhai Wang
  • Publication number: 20190194299
    Abstract: The present invention provides antibodies that neutralize MERS-CoV and methods of use thereof. The invented antibody is used to treat MERS-CoV infections and symptoms thereof.
    Type: Application
    Filed: November 19, 2018
    Publication date: June 27, 2019
    Inventors: Wayne A. Marasco, Xianchun Tang
  • Publication number: 20190194300
    Abstract: The present disclosure provides fully human variant anti-AIP2 variant antibodies, and antigen binding proteins thereof, having improved characteristics compared to the wild type anti-AIP2 antibody E7 from which the variant clones are derived. The variant anti-AIP2 antibodies exhibit improved binding to AIP1 and AIP4 as determined in an in vitro quorum sensing reporter assay, have improved thermal stability, provided complete protection against infection with two different strains of Staphylococcus aureus MRSA in pre-treated mice, and can be manufactured at higher yields.
    Type: Application
    Filed: December 20, 2018
    Publication date: June 27, 2019
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Yanliang Zhang, Gunnar F. Kaufmann
  • Publication number: 20190194301
    Abstract: The invention provided Mucorales CotH antibodies, polypeptides, encoding nucleic acid molecules, and uses thereof. The Mucorales CotH antibodies, polypeptides and encoding nucleic acids disclosed herein can be advantageously used to diagnose, treat or prevent fungal conditions, in particular mucormycosis.
    Type: Application
    Filed: December 11, 2018
    Publication date: June 27, 2019
    Inventors: Ashraf S. Ibrahim, Mingfu Liu, Teklegiorgis Ghebremariam, Yue Fu, John E. Edwards, Scott Filler
  • Publication number: 20190194302
    Abstract: Methods are provided for the manufacture of polypeptides comprising at least one immunoglobulin variable domain that result in an increased yield. The methods are based on simultaneous enhancement of one or more auxiliary proteins in the host.
    Type: Application
    Filed: February 10, 2017
    Publication date: June 27, 2019
    Applicant: Ablynx N.V.
    Inventors: Peter SCHOTTE, Manu DE GROEVE
  • Publication number: 20190194303
    Abstract: Methods for making modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Antibodies comprising Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided.
    Type: Application
    Filed: October 2, 2018
    Publication date: June 27, 2019
    Inventors: Chi-Huey WONG, Chung-Yi WU
  • Publication number: 20190194304
    Abstract: The invention relates to isolated, synthetic or recombinant antibodies and fragments thereof specific for factor H. The invention further relates to the use of such antibodies and fragments for inhibiting complement activation and treatment of disorders associated with complement activation.
    Type: Application
    Filed: October 29, 2018
    Publication date: June 27, 2019
    Inventors: Taco Willem Kuijpers, Diana Wouters, Maria Clara Brouwer, Richard Benjamin Pouw
  • Publication number: 20190194305
    Abstract: The invention relates to an anti-human p53 antibody suitable for specifically binding a linear epitope which is exposed only in a conformationally altered isoform of the characteristic p53 protein of patients with Alzheimer's disease or prone to develop Alzheimer's disease or cognitive impairment during ageing. Methods and diagnostic and prognostic kits are also described.
    Type: Application
    Filed: December 10, 2018
    Publication date: June 27, 2019
    Applicant: DIADEM S.R.L.
    Inventors: Maurizio MEMO, Daniela Uberti
  • Publication number: 20190194306
    Abstract: The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4(=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein.
    Type: Application
    Filed: December 18, 2018
    Publication date: June 27, 2019
    Inventors: Christof NIEHRS, Wei WU, Andrey GLINKA, Olga KAZANSKAYA
  • Publication number: 20190194307
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Application
    Filed: March 8, 2019
    Publication date: June 27, 2019
    Inventors: Caroline BARELLE, Mischa Roland MULLER, Valarie CALABRO, Jack BIKKER, John STEVEN, Lioudmila TCHISTIAKOVA, Oleg KOVALENKO, Andrea OLLAND
  • Publication number: 20190194308
    Abstract: The present invention relates to bispecific antibodies having activity against a vascular endothelial growth factor (VEGF) and an angiopoietin (ANG), and methods of making and using such bispecific antibodies.
    Type: Application
    Filed: August 22, 2017
    Publication date: June 27, 2019
    Inventors: Ching Ching Leow, Nazzareno Dimasi, Karen Coffman, Ryan Fleming, Ping Tsui, Changshou Gao, Mario A. Cepeda, Adrian Schwartz Mittelman
  • Publication number: 20190194309
    Abstract: Disclosed are monoclonal antibodies that bind specifically to macrophage stimulating protein receptor (or RON—Recepteur d' Origine Nantais). Also provided are the chimeric antigen receptors, bispecific antibodies, bivalent antibodies and biTE thereof, as well as pharmaceutical compositions and uses of said antibodies for the treatment of cancer and fibrosis and an ex vivo method of evaluating the status of a cancer patient using said antibodies. In particular, two monoclonal antibodies, 7G8 and 6D4, demonstrating good therapeutic efficacy in inhibiting tumour growth in human xenograft mice models and sensitivity in human xenograft mouse tumour imaging models are provided.
    Type: Application
    Filed: August 28, 2017
    Publication date: June 27, 2019
    Inventors: David LANE, Xin Yu KOH, Le-Ann HWANG
  • Publication number: 20190194310
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Application
    Filed: March 16, 2017
    Publication date: June 27, 2019
    Applicant: Numab Innovation AG
    Inventors: Tea GUNDE, Sebastian MEYER
  • Publication number: 20190194311
    Abstract: The present disclosure relates to methods for treating new-onset plaque-type psoriasis patients and inhibiting the progression of structural damage in these patients, using Interleukin-17 (IL-17) antagonists, e.g., secukinumab. Also disclosed herein are uses of IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating new-onset plaque-type psoriasis patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.
    Type: Application
    Filed: July 18, 2017
    Publication date: June 27, 2019
    Inventors: Andreas Fasth, Jaime Oliver
  • Publication number: 20190194312
    Abstract: Improved IL-6 antibodies are provided. Uses of the antibodies in the treatment of IL-6 related diseases, e.g., ocular diseases such as diabetic macular edema, are disclosed.
    Type: Application
    Filed: November 6, 2015
    Publication date: June 27, 2019
    Inventors: Michael March Schmidt, Alison Tisdale, Eric Steven Furfine, Grigorios Zarbis-Papastoitsis